Top > News & Information > A new paper has been published.
A new paper has been published.
A new study performed in collaboration with Prof. Hiroshi Handa, Tokyo Medical University, Prof. Masahiro Kizaki, Saitama Medical University, and others has been published in
Nature Chemical Biology. This study offers insights into how the drug pomalidomide benefits some patients with a cancer called multiple myeloma. Clinicians use pomalidomide to treat cases of multiple myeloma resistant to the more established drug lenalidomide, and the research team found that pomalidomide works by targeting a protein called ARID2. These findings may lead to new treatments for lenalidomide-resistant multiple myeloma. For more detail, please also see our
Press Release.